Literature DB >> 11902513

Variations in treatment and survival in breast cancer.

A D Purushotham1, S J Pain, D Miles, A Harnett.   

Abstract

To achieve optimum quality of care for women with breast cancer in the UK, uniformity of care in accordance with consensus guidelines is needed. This review highlights variations in provision of care for women with breast cancer, with particular emphasis on care received in the UK, examines differences in survival, and discusses the factors that may underlie these differences. Strong variation in treatment was identified, which appeared to affect survival significantly. These findings reinforce the need for women with breast cancer to be treated by dedicated specialists working within a multidisciplinary team to provide a high standard of care.

Entities:  

Mesh:

Year:  2001        PMID: 11902513     DOI: 10.1016/s1470-2045(01)00585-x

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  4 in total

1.  Life after the cancer strategy: analysis of surgical workload in the general hospital setting.

Authors:  E Concannon; I Robertson; F Bennani; W Khan; R Waldron; K Barry
Journal:  Ir J Med Sci       Date:  2013-01-22       Impact factor: 1.568

2.  Mammography screening in the Netherlands: delay in the diagnosis of breast cancer after breast cancer screening.

Authors:  L E M Duijm; J H Groenewoud; F H Jansen; J Fracheboud; M van Beek; H J de Koning
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

3.  Breast cancer risk is increased in the years following false-positive breast cancer screening.

Authors:  Mathijs C Goossens; Isabel De Brabander; Jacques De Greve; Evelien Vaes; Chantal Van Ongeval; Koen Van Herck; Eliane Kellen
Journal:  Eur J Cancer Prev       Date:  2017-09       Impact factor: 2.497

4.  Clinical outcome data for symptomatic breast cancer: the Breast Cancer Clinical Outcome Measures (BCCOM) Project.

Authors:  T Bates; O Kearins; I Monypenny; C Lagord; G Lawrence
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.